Gabapentin and Skin atrophy - a phase IV clinical study of FDA data

Summary:

Skin atrophy is reported as a side effect among people who take Gabapentin (gabapentin), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Lasix, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Skin atrophy when taking Gabapentin. It is created by eHealthMe based on reports of 313,421 people who have side effects when taking Gabapentin from the FDA, and is updated regularly.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 322,983 Gabapentin users. Check the latest studies of Gabapentin.

What is Skin atrophy?

Skin atrophy (wasting of skin) is found to be associated with 624 drugs and 716 conditions by eHealthMe. Check the latest studies of Skin atrophy.

On Jul, 23, 2026

313,421 people reported to have side effects when taking Gabapentin.
Among them, 209 people (0.07%) have Skin atrophy.

Among these 209 people:

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and have Skin atrophy?

- Check whether Skin atrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gabapentin:

Gabapentin (322,983 reports)

Skin atrophy treatments and more:

Skin atrophy (6,670 reports)

How severe was Skin atrophy and when was it recovered:

Skin atrophy in Gabapentin

Expand to all the drugs that have ingredients of gabapentin:

Skin atrophy and drugs with ingredients of gabapentin (100 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gabapentin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin atrophy:

Skin atrophy (624 drugs)

Browse all the conditions that are associated with Skin atrophy:

Skin atrophy (716 conditions)

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Gabapentin) and Gabapentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.